E-Posters-10256

10256_Bickhaus

Pdf Summary

This study aimed to investigate the association between early post-injection urinary tract infection (UTI) and recurrent UTIs after onabotulinum toxin A (BTX) treatment. The study included women who received their first BTX injection between 2010 and 2015 and followed them for one year. UTI was defined as a positive urine culture or empiric treatment based on symptoms. Recurrent UTI was defined as more than two UTIs within six months or more than three UTIs within one year post-injection. <br /><br />The study found that early UTI within 30 days of injection was a risk factor for recurrent UTIs in the subsequent year, even after adjusting for a history of recurrent UTI. Furthermore, early UTI remained a risk factor for recurrent UTIs even after adjusting for the need for catheterization. The study suggests that further research should be conducted to minimize recurrent UTIs, particularly in patients who experience a UTI within 30 days of BTX treatment. <br /><br />Previous studies have shown that BTX injections are effective for treating overactive bladder, but UTIs are a common adverse event, occurring in 33-35% of cases. Recurrent UTIs can be a reason for discontinuing BTX treatment, and little is known about this topic. <br /><br />Overall, the study highlights the importance of identifying early UTIs after BTX treatment and taking steps to minimize recurrent UTIs in order to optimize patient outcomes.

Keywords

association

early post-injection

urinary tract infection

UTI

recurrent UTIs

onabotulinum toxin A

BTX treatment

women

urine culture

empiric treatment